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Acromegaly and gigantism are due to excess GH production, usually as a result of a pituitary adenoma. The incidence of acromegaly
is 5 cases per million per year and the prevalence is 60 cases per million. Clinical manifestations in each patient depend on the levels
of GH and IGF-I, age, tumor size, and the delay in diagnosis. Manifestations of acromegaly are varied and include acral and soft
tissue overgrowth, joint pain, diabetes mellitus, hypertension, and heart and respiratory failure. Acromegaly is a disabling disease
that is associated with increased morbidity and reduced life expectancy. The diagnosis is based primarily on clinical features and
confirmed by measuring GH levels after oral glucose loading and the estimation of IGF-I. It has been suggested that the rate of
mortality in patients with acromegaly is correlated with the degree of control of GH. Adequately treated, the relative mortality risk
can be markedly reduced towards normal.
1. Introduction
Acromegaly and gigantism are due to excess GH production,
usually caused by a pituitary adenoma. The diagnosis is often
preceded by around 10 years of active but unrecognized
disease [1]. Pituitary adenomas account for approximately
15% of all intracranial tumors. The incidence of acromegaly
is approximately 5 cases per million per year and the preva-
lence is 60 cases per million [2]. Somatotroph adenomas
are monoclonal in origin and develop from genetic changes.
Other contributors that could facilitate the expansion of
the somatotroph tumor cells are hypothalamic GHRH or
somatostatin, paracrine growth factors, and ghrelin [1, 3].
Recent data suggest the importance of the role of ghrelin in
the pathophysiological regulation of GH [4–6]. Over 90% of
patients with acromegaly have a benignmonoclonal pituitary
adenoma, which are not surrounded by hyperplasic tissue.
Densely granulated adenomas grow slowly and occur in
patients over the age of 50. Sparsely granulated adenomas
grow faster and occur in younger patients.
Some 25% of GH-secreting adenomas also secrete pro-
lactin. These include dimorphic adenomas with GH and pro-
lactin cells, monomorphic mammosomatotroph adenomas,
and more primitive acidophilic cell adenomas. Multicellular
or unicellular immunoreactivity is common, especially for
the alpha subunit of glycoprotein hormones. The secretion of
other hormones has very uncommon clinical consequences
[7]. Over 70% of somatotroph adenomas are macroade-
nomas at diagnosis, but somatotropic cell carcinoma is
exceptional. The ectopic secretion of GH is equally outstand-
ing. Familial syndromes of acromegaly are rare. Excessive
production of GHRH from central hypothalamic sources
(usually gangliocytomas) or peripheral sources can lead to
somatotroph hyperplasia and acromegaly [8].
The manifestations of acromegaly are varied, including
acral and soft tissue overgrowth, joint pain, diabetes mellitus,
hypertension, and heart and respiratory failure. It has been
suggested that the mortality rate in acromegalic patients
is correlated with the degree to which GH hypersecretion
is controlled. The decreased survival rate associated with
acromegaly can be normalized by successful surgical and
adjunctive therapy. The mortality rate of cancer can be
stratified according to the level of GH treatment and may be
similar to that of the general population. Analyzing mortality
determinants, around 60% of acromegalic patients die from
cardiovascular disease, 25% from respiratory causes, and
15% from neoplasias [9].
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2. Clinical Manifestations
Clinical manifestations in each patient depend on the
levels of GH and IGF-I, age, tumor size, and the delay
in diagnosis. The typical features of acromegaly slowly
develop over years; around 40% of acromegalic patients are
diagnosed by internists, ophthalmologists if they have visual
disturbances, dentists due to maxillary teeth separation,
mandibular prognathism, and overbite, gynecologists due
to menstrual irregularities and infertility, rheumatologists if
they suﬀer form joint problems, or pulmonologist if they
have obstructive sleep apnea [10] (Table 1). GH is also
implicated in other actions that are not mediated by IGF-I,
such as anti-insulin, lipolytic, and antinatriuretic eﬀects. A
recent study found that excess GH in humans is associated
with increased activity of the epithelial sodium channel,
and this could contribute to the volume expansion and soft
tissue manifestations seen in acromegaly [11]. GH secreting
pituitary adenomas in children before growth is complete
cause gigantism. Pituitary gigantism is very rare: in a total
sample of 2367 children and adolescents with pituitary
adenomas, only 0.6% had gigantism [12].
The growth of the pituitary adenoma may compress
local structures and cause neurological symptomatology and
visual disturbances. Somatotroph adenomas grow slowly,
and patients presenting these adenomas are usually older
than 50 years. Changes in appearance derive from skeletal
growth and soft tissue enlargement, which is subtle in the
early stage of the disease. Visceromegalies are common, in the
form of goiter, hepatomegaly, splenomegaly, and macroglos-
sia. Facial changes include large lips and noses, frontal skull
bossing and cranial ridges, mandibular overgrowth with
prognathism, maxillary widening with teeth separation, jaw
malocclusion, and overbite. Growth occurs on acral parts,
with an increase in shoe and ring size [13].
The clinical manifestations of acromegaly include skin
changes such as hyperhidrosis, oily skin, and unpleasant
odor, which are due to the deposit of glycosaminoglycans.
Pigmented skin tags over the trunk are common in patients
with acromegaly; it is not clear whether GH/IGF-I excess
causes skin tags directly, or whether they arise as a con-
sequence of insulin resistance and dyslipidemia. Acanthosis
nigricans develop in patients with severe acromegaly, where
the skin in the axillae and back of the neck becomes
dark, soft, and velvet-like with delicate folds and papillae.
This phenomenon is caused by increased amounts of skin
extracellular matrix, accompanied by edema. Cutaneous
microcirculation is altered in patients with acromegaly. Rare
manifestations include cutis verticis gyrate and psoriasis.
These manifestations respond well to decreased GH level;
although some changes are irreversible [14].
2.1. Osteoarticular Manifestations. One of the most frequent
clinical manifestations of acromegaly aﬀects the joints, in
approximately 70% of individuals at the time of diagnosis.
Articular alterations are the most frequent and severe
cause of morbidity and disability in these patients. The
pathogenesis of arthropathy in acromegaly is comprised
of two mechanisms: initial endocrine elevated GH and
Table 1: Clinical manifestations of acromegaly.
Mass eﬀects of the tumor
Headache
Visual field defects
Hyperprolactinemia
Pituitary stalk section
Hypopituitarism
Hypothyroidism, hypogonadism, hypocortisolism
Systemic eﬀects of GH/IGF-I excess
Visceromegaly
Soft tissue and skin changes
Thickening of acral parts
Increased skin thickness and soft tissue hypertrophy
Hyperhidrosis/Oily texture
Skin tags and acanthosis nigricans
Cardiovascular features
Hypertrophy (biventricular or asymmetric septal)
Congestive Heart Failure (systolic and/or diastolic)
Coronary disease
Arrhythmias
Hipertensio´n
Cardiomyopathy
Metabolic features
Impaired glucose tolerance
Diabetes mellitus
Insulin resistance
Respiratory manifestations
Macroglossia
Jaw malocclusion
Upper airway obstruction
Sleep disturbances
Sleep apnea (central and obstructive)
Ventilatory dysfunction
Bone and joint manifestations
Increased articular cartilage thickness
Arthralgias and arthritis
Carpal tunnel sı´ndrome
Osteopenia
Other endocrine consequences
Goiter
Hypercalciuria
Galactorrhea
Decrease libido, impotents
Menstrual abnormalities
Modified from Cordero and Barkan [61].
IGF-I levels promote growth of the articular cartilage and
periarticular ligaments, subsequently leading to mechanical
changes. Arthralgia is one of the most common complaints
of acromegalic patients. Large joint arthropathy is a common
feature of the disease, occurring in approximately 70% of
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patients, resulting from the thickening of cartilaginous and
periarticular fibrous tissue, causing joint swelling, pain, and
hypomobility followed by the narrowing of joint spaces,
osteophytosis, and features of osteoarthritis with chronic
disease [15]. Approximately 50% of patients have axial
arthropathy (disk space widening, vertebral enlargement,
and osteophyte formation) mainly aﬀecting the lumbar area.
Aﬀectation of the lumbar area can cause restricted range of
movement, joint instability, and deformity of joint.
The radiological appearance of arthropathy in acromeg-
aly was studied in small noncontrolled groups of patients
with the disease treated or untreated, but active. These
studies have suggested that more severe radiological changes
are associated with disease duration and activity. The most
prevalent manifestation was axial osteoarthritis, aﬀecting the
cervical and lumbar areas, even at young ages. The charac-
teristic radiological changes observed were wide joint spaces
and severe osteophytosis. This study documents that the risk
to develop osteoarthritis is predicted by IGF-I concentrations
at the time of initial diagnosis. These associations were not
caused by diﬀerences in age, gender, or BMI [16]. The carpal
tunnel syndrome occurs in approximately 30% to 50% of
acromegalic patients and is frequently bilateral. The pre-
dominant pathology of median neuropathy in acromegaly
consisted of increased edema of the median nerve in the
carpal tunnel, rather than extrinsic compression due to
increased volume of the carpal tunnel contents [15].
Although acromegaly is often included in lists of endo-
crinopathies associated with osteoporosis, due to increased
bone turnover, some investigators have reported normal or
increased bone mass in this disorder [17, 18]. The eﬀects of
excess GH on bone mineral density are variable in relation to
the skeletal area, as a result of diﬀering sensitivity to excess
GH of the trabecular and cortical bone [19]. Decreased bone
mineral density has been reported in acromegaly almost
exclusively at the lumbar spine, a site rich in trabecular bone,
whereas increases in bone mineral disease may be observed
in the forearm, a site rich in cortical bone. The variability
of data on bone mineral density in acromegaly may also be
explained by the diversity of the densitometric techniques
used, age and gender. Some of the inconsistencies in the
literature may be accounted for as a result of the common
association between acromegaly and hypogonadism. The
impact of hypogonadism should therefore be considered in
patients with acromegaly when evaluating bone density. GH
and IGF-I have a stimulatory eﬀect on osteoblast function,
and several studies indicate a potential anabolic eﬀect of GH,
at least on the cortical bone. Altogether, these data suggest
that excess GH and IGF-I induce an increase of the cortical
bone density, independently of gonadal function, whereas
hypogonadism seems to counteract the anabolic eﬀect of GH
on the trabecular bone [20, 21].
Chronic excess of GH and IGF-I typically aﬀects the
axial skeleton with the development of severe alterations to
the spine morphology and function until features of diﬀuse
idiopathic skeletal hyperostosis occur. An early diagnosis of
acromegaly is mandatory in order to reduce the severity
of spine abnormalities as they are significantly higher in
patients with longer disease duration [22].
2.2. Cardiovascular Manifestations. Cardiovascular manifes-
tations occur in 60% of patients. Elevated growth hormone,
hypertension, and heart disease are negative determinants
for life expectancy in acromegaly. Therefore controlling GH,
hypertension, and heart disease are relevant in decreasing
mortality rate. Cardiac involvement in acromegaly, in the
absence of other contributing factors, is called acromegalic
cardiomyopathy, which is initially characterized by cardiac
hypertrophy, followed by diastolic dysfunction and ulti-
mately failure of systolic function [23]. This situation is
aggravated by the presence of other complications, such
as diabetes or hypertension [24]. There is a reported case
of death due to heart failure secondary to cardiomyopathy
induced by acromegaly and aggravated by obesity [25]. The
presence of arrhythmias (atrial fibrillation, supraventricular
tachycardia, and ventricular arrhythmias) is also more com-
mon, especially during exercise [26]. Valvular disorders are
underestimated and are related to the degree of hypertrophy
[27]. Despite this unfavorable cardiovascular risk profile, it
is unknown whether acromegalic patients have an increased
risk of coronary artery disease.
Some authors have found an increased thickness of the
intima-media layer, depending on factors such as smoking
[28]. Several studies have revealed that there are atheroscle-
rotic changes in patients with acromegaly related to the time
of evolution. In a study by Colao et al. a significant increase
of intima-media thickness of both common carotid arteries
was observed in patients with active acromegaly, as well as in
patients whose acromegaly had been cured. However, there
was no increase in the prevalence of well-defined carotid
plaques in either of the patient groups in comparison to
controls [28]. Another study found that coronary artery
disease risk in newly diagnosed acromegalic patients was low
and remained stable after successful treatment [29].
In acromegalic patients, the Framingham score was cal-
culated and screening for calcification of the coronary
arteries was carried out using computed tomography. The
authors found a 40% risk [30], in contrast to another
study in which the cardiovascular risk calculated by the
Framingham score was low [31], although both previous
studies included heterogeneous groups of patients with
controlled and uncontrolled disease activity. In a more recent
study, cardiovascular risk factors were studied in patients
with acromegaly. An increased rate of hypertension and
diabetes was found, triglyceride levels were elevated, and
high- and low-density lipoproteins were low. Cardiovascular
risk calculation has shown that patients with acromegaly are
at greater risk, particularly female patients, and that this
risk decreased with normalization of IGF-I [32]. Arterial
hypertension is considered to be one of the most important
prognostic factors for mortality [33]. It is present in one-
third of acromegalic patients, and diﬀerent mechanisms are
considered to be responsible, including increased plasma
volume, alterations in renin-angiotensin, insulin resistance,
and increased vascular resistance.
Excess GH can cause insulin resistance, as it alters the
ability of insulin to suppress glucose production and stimu-
lates its use [34]. Intolerance to carbohydrates and diabetes
mellitus are frequently associated with acromegaly. The
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prevalence of diabetes mellitus in acromegaly is estimated
to be 19 to 56%, in diﬀerent series [35]. Carbohydrate
intolerance occurs with a prevalence of 31% in the study by
Biering et al. [36], 46% in the study of Kasayama et al. [37],
and 16% in the analysis carried out by Kreze et al. [35]. The
most characteristic predisposing factors for diabetes were
older age and longer duration of illness. In the study of
Kreze et al. [35] diabetes is influenced by a family history
of diabetes and the presence of hypertension. Other factors
proposed by Colao et al. [38] are the presence of concomitant
hyperprolactinemia, tumor size, and a family history of
diabetes. Diabetes is also associated with abnormalities in
lipid metabolism, such as a tendency towards having low
cholesterol levels and hypertriglyceridemia. Not all studies
have identified these outcomes [39]. In most cases, when the
acromegaly is cured, this leads to the disappearance of insulin
resistance and therefore the disappearance of diabetes.
The possible association between intracranial aneurysms
and pituitary adenoma has been frequently debated. A recent
study documents an increased prevalence of intracranial
aneurysms in acromegaly and the presence of intracranial
aneurysms correlated with GH serum values at disease onset
and showed a trend to a positive correlation with poor
disease control [40].
2.3. Respiratory Manifestations. Acromegaly alters the struc-
ture of the respiratory apparatus and impairs respiratory
function. Patients with acromegaly develop a number of res-
piratory alterations, as a consequence of anatomical changes
aﬀecting the craniofacial bones and soft tissues, respiratory
mucosa/cartilages, lung volumes, rib cage geometry, and the
activity of respiratory muscles. This range of abnormalities
results in two main respiratory dysfunctions, namely, sleep
apnea and impaired respiratory function. Sleep apnea, the
phenomenon of recurrent cessation or reduction of airflow
to the lungs during sleep, is a common cause of snoring and
daytime sleepiness in acromegaly. Impaired respiratory func-
tion is less frequently investigated in acromegaly and origi-
nates from multiple alterations involving the bone and mus-
cle structure of the chest as well as lung elasticity. Lung vol-
umes become increased in patients with acromegaly and they
may develop subclinical hypoxemia. The impact of respira-
tory complications is high in acromegaly, and patients with
this condition may have increased respiratory mortality [41].
Patients with acromegaly develop a barrel chest due to
changes in their vertebral and costal morphology. Obstruc-
tion of the upper airways is a result of macroglossia, prog-
nathism, thick lips, and hypertrophy of the laryngeal mucosa
and cartilage; it can cause sleep apnea and excessive snoring
and can complicate tracheal intubation during anesthesia.
Hypoventilation and hypoxemia may also arise from central
respiratory depression and kyphoscoliosis. The lungs show
increased distensibility with normal diﬀusion capacity [42].
Moreover, using polysomnography, Attal and Chanson
[43] found an average rate of 69% for obstructive sleep
apnea in patients with active disease in prospective or
retrospective studies. Sleep apnea occurs in more than 50%
of patients. In patients with acromegaly, obstructive sleep
apnea predominates over central sleep apnea (which may
be observed in some patients and was considered to be a
consequence of an increased ventilation response to carbon
dioxide) and has been linked to changes in the facial skeleton,
jaw opening, and to increased laryngeal soft tissue. Another
factor to consider is obesity experienced by patients with
acromegaly. Medical or surgical treatment of acromegaly
improves obstructive sleep apnea in a substantial number
of patients, but according to several prospective studies it
persists in up to 40%. This provides us with an insight
into the multifactorial etiology of obstructive sleep apnea in
acromegaly [44, 45].
2.4. Endocrinological and Other Manifestations. Hyperpro-
lactinemia with or without galactorrhea develops in approx-
imately 30% of patients due to of pituitary stalk compression
or mixed tumor secretion of GH and PRL. Hypopituitarism,
by mass compression of the normal pituitary tissue, occurs
in approximately 40% patients; amenorrhea, impotence, or
secondary thyroid or adrenal failure may develop. Goiter
and thyroid abnormalities are common, potentially as a
result of the stimulating eﬀects IGF-I on thyrocyte growth.
Hyperthyroidism rarely develops because of high levels of
serum thyrotropin secreted from plurihormonal pituitary
tumors. Hypercalcemia in acromegaly is reported in up to
8% of patients; it is usually secondary to coexistent hyper-
parathyroidism and does not resolve after treatment of excess
GH. Reports indicate that hypercalciuria and nephrolithiasis
may occur in 6–77% of patients with acromegaly. Proposed
mechanisms of hypercalciuria include parathyroid hyperpla-
sia, renal tubular acidosis, increased calcium absorption, and
overproduction of 1, 25 (OH)2 D [46].
One study evaluated sleep characteristics in a small
group of acromegalics; an astonishingly high number of
patients were found to be aﬀected by restless leg syndrome,
a neurological disorder characterized by a compelling urge
to move the limbs during the night, due to unpleasant
paraesthetic sensory symptoms, which may lead to severe
insomnia, consequent daytime sleepiness, and reduced
quality of life. The study found that the prevalence and
severity of restless leg syndrome is increased in patients with
active acromegaly and impacts negatively on their physical
performance, dramatically impairing quality of life [47].
2.5. Gastrointestinal Manifestations. The gastrointestinal
manifestations associated with acromegaly are colon carci-
noma, adenomatous polyps, and dolichocolon. In a recent
study, colonic diverticular disease was found to be higher
in patients with acromegaly when compared with controls,
and diverticula were present at a significantly younger
age. Diverticulosis in acromegaly was primarily associated
with the duration of the active disease, which became
even stronger when adjusted for excess GH and IGF-I.
Dolichocolon and adenomatous polyps were increased in
patients when compared with controls, both of which were
associated with IGF-I concentrations at the time acromegaly
was diagnosed [48].
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Epidemiological studies have reported conflicting find-
ings on cancer risk in acromegaly [49, 50]. Diﬀerent studies
on the risk of prostate, breast, colorectal, lung, and thyroid
cancer suggest that high circulating IGF-I levels are related
to an elevated risk of cancer, whereas high levels of insulin-
like growth factor binding protein type 3 (IGFBP-3) levels
are associated with a reduced risk. GH has a stimulatory
eﬀect on both IGF-I and IGFBP-3, and therefore there should
not be an increased risk of malignancy. Excess GH causes
an elevated IGF-I to IGFBP-3 ratio, which is expected to
increase cancer risk. The question of whether or not elevated
GH and IGF-I levels result in de novo cancer initiation
remains unresolved. The cancers most frequently studied
in acromegaly are colon, breast, and prostate carcinomas,
although many others have been described including hema-
tological, bronchial, gastric, esophageal, thyroid, osteosar-
coma, pancreas, melanoma, ovarian, renal, adrenal, biliary,
carcinoid, cervix, bladder, parotid, astrocytoma, and small
intestine cancer.
Patients with acromegaly have a higher prevalence of
colorectal neoplasms. The pathogenic mechanisms are still
unclear and may be related to a sustained increase in serum
GH-IGF-I, hyperinsulinemia, altered IGFBP-3, increased
IGF-II and IGFBP-2 levels, altered local immune response,
and genetic susceptibility. Elevated levels of serum IGF-I
are associated with increased proliferation in the superficial
crypt cells. Colao et al. investigated the relationship of GH,
IGF-I, and insulin levels to colonic lesions in a cohort
of consecutive newly diagnosed patients with acromegaly
and found that fasting insulin levels were associated with
premalignant and malignant colonic lesions. It was also
found that glucose tolerance and insulin levels were strongly
associated with colonic adenomas and carcinomas. Diabetes
or impaired glucose tolerance was a risk factor for the
development of colonic lesions [51].
Considering all the prospective colonoscopy screening
studies, an increased prevalence of colorectal cancer has
been found in acromegaly when compared with controls.
No increase was demonstrable if acromegaly was controlled,
but if the disease was active, premalignant polyps were more
frequent and increased their tendency to become malignant.
Once developed, the cancer was more aggressive, with
higher mortality. A positive correlation between mortality
from colorectal cancer and disease activity was observed.
Therefore, complete colonoscopy should be oﬀered, and at
least a baseline one at diagnosis colonoscopy assessment
is required in all patients with acromegaly [52]. Multiple
skin tags, a positive family history or any other genetic
predisposition, or advancing age are considered as predis-
posing features to consider colon cancer. Screening will
depend on the initial findings, whether IGF-I is normal
or high, and on the patient’s age. Whether colonoscopy
should be performed every 3 or 5 years is not defined. If
acromegaly is controlled and no polyps are initially found,
it is unclear whether subsequent colonoscopy is necessary
at all. In summary, since there seems to be an increased
prevalence of colorectal neoplasms in acromegaly, regular
screening and polypectomy if required would seem advisable
[53]. In principle, as there is a relationship between GH
and IGF-I in serum and cancer, the most eﬀective the
treatment of acromegaly is, the less should be the mortality
from colorectal cancer [54]. Further studies are necessary
to evaluate the true incidence of prostate and breast cancer
and hematological malignancies in acromegaly [55]. The
similarity between the epithelial tissue of the gallbladder
and colon raises the possibility that gallbladder polyps may
occur more frequently in acromegaly. A recent study has
demonstrated an increased prevalence of gallbladder polyps
in patients with newly diagnosed acromegaly. Further studies
are required to determine whether these patients are at
increased risk of developing gallbladder carcinoma and to
define the role, if any, of biliary ultrasound surveillance [56].
3. Diagnosis
Acromegaly is an insidious disease, which is often diagnosed
late (between 4 and more than 10 years after onset).
The increase in morbidity and mortality associated with
acromegaly is the result of the oversecretion GH and IGF-I
and the direct mass eﬀect of the pituitary tumor. An early
diagnosis of the disease is mandatory, although none of these
symptoms is suﬃciently sensitive, especially during early
stages of the disease. Physiognomic alterations and growth
of the acral parts are the first manifestations of the disease
in most cases; this is the reason for a medical visit in most
patients. Growth of the acral parts is uncommon in adults
without acromegaly and can be objectively evaluated by an
increase in shoe and/or ring size. Therefore, familiarization
of physicians with the phenotype of the disease may be more
eﬀective in order to increase the diagnosis and to permit early
detection, rather than strategies addressing comorbidities,
which are not always present, usually appear later, and are
rarely seen in the absence of the acromegaly phenotype [57].
Another possible method for early diagnosis of patients with
acromegaly is to use software in order to detect the features
of acromegaly, using photographs of the face. This could be
a promising system for identifying the disease [58].
When there is clinical suspicion of the disease, bio-
chemical confirmation is required to establish the diagnosis
(Figure 1). Normal GH production from the pituitary gland
is pulsatile; most GH values fall in the range of 0.1-0.2 μg/L in
normal subjects, with the maximum production occurring at
night in harmony with sleep stages. However there are six to
ten secretory bursts during the day, when GH reaches values
of 5–30 μg/L, which may overlap with the values seen in
acromegalic patients. The diagnosis of acromegaly requires
elevated levels of GH and IGF-I to be demonstrated. The
best way to assess overall daily GH production is to obtain
a mean GH over 24 h by frequent GH sampling, although
this method is inconvenient and 24-h mean GH values have
been found to overlap with those of healthy controls [59].
Initial studies assumed that a 0800 hours GH value correlated
well with mean 24 h GH; however further studies revealed
discrepancies. Furthermore, studies have shown that GH
secretion is influenced by age and body mass index, so both
diagnostic and surveillance GH levels should be interpreted
in the context of age.
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Figure 1: Algorithm for the diagnosis of acromegaly (modified from: Cordero and Barkan [61] and Giustina et al. [63]).
GH levels are tonically elevated in acromegaly, so a
random GH value of less than 0.04 μg/L excludes the
diagnosis [1], although an elevated random value does not
imply their presence. The standard method for diagnosing
acromegaly has been to measure the GH nadir during an
oral glucose tolerance test (OGTT), which is undetectable in
normal individuals, while acromegalics fail to suppress GH
levels. It is useful to determine IGF-I levels as they correlate
with the clinical features of acromegaly and with the 24-
hour mean GH levels. The standard OGTT consists of the
administering of 75 g of glucose with GH measurements at
various time points for up to 120 minutes [60].
IGF-I has been used as a marker of disease activity in
acromegaly. It is mainly synthesized in the liver, although
nearly all of the tissues contribute to the circulating con-
centration. It is an ideal screening test as it has a long half
life of 18–20 hours and the levels remain stable throughout
the day. IGF-I is aﬀected by age and gender, decreasing
by approximately 14% per decade during adult life. Some
disorders including malnutrition, malabsorption, anorexia
nervosa, liver cirrhosis, renal failure, type 1 diabetes mellitus,
normal pregnancy, and adolescence show discrepancies
between GH and IGF-I [61]. The development of radioim-
munoassay (RIA) provided clinicians with a biochemical
tool to diagnose acromegaly. Many limitations were inherent
to this methodology, which required the development of
more sensitive tools, such as immunoradiometric (IRMA)
or immunoluminometric (ILMA) assays for GH and IGF-I
measurements. The reference ranges to describe normalcy of
the somatotropic axis and the biochemical criteria of “cure”
of acromegaly are areas of great debate [62].
Biochemical diagnosis is made by determining of GH
after OGTT with 75 g and determining the levels of IGF-I.
The current international consensus for the diagnosis of
acromegaly recommends a nadir GH equal to or greater
than 0.4 μg/L after an OGTT, in conjunction with clinical
suspicion and high IGF-I levels [63]. The diagnosis is
sometimes complicated by the physiological variations of GH
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and the lack of uniformity of methods for GH determina-
tion. The new monoclonal antibody-based immunoassays
are more sensitive, although they suﬀer from significant
problems in terms of reproducibility [64]. GH cannot
be suppressed in the presence of liver failure, kidney
failure, poorly controlled diabetes, malnutrition, anorexia,
pregnancy, estrogen therapy, or in late adolescence [1]. In
contrast, a recent study [65], found that 7 adult patients
with newly diagnosed untreated acromegaly out of a total
group of 40 had a GH nadir after an OGTT of less than
0.4 μg/L. These data highlight the limited diagnostic value of
OGTT in patients with biochemically active acromegaly but
only mildly increased GH output and the limitations for the
applicability of consensus guidelines on diagnosis in clinical
practice [66].
In diﬀerent situations IGF-I serves as a biomarker of the
activity of acromegaly. IGF-I levels are relatively stable and
correlate with clinical acromegaly and elevated GH levels. In
order to accurately assess IGF-I levels, age-matched controls
are required, as the levels of IGF-I decreased 14% per decade.
In order to monitor disease activity, levels of GH and IGF-
I are complementary. It has been suggested that in the
presence of discordant serum IGF-I and GH levels, IGF-I
is more predictive than GH in terms of insulin sensitivity
and clinical symptom score [67]. The measurement of the
acid-labile subunit, other binding proteins (such as IGF-
binding protein-3), or ghrelin oﬀers no advantage over
IGF-I measurement in the diagnosis and management of
acromegaly [63].
As previously mentioned, pituitary GH-secreting tumors
may cosecrete other hormones. Hyperprolactinemia may be
due to cosecretion or pituitary stalk compression. Mass eﬀect
of the tumor may aﬀect the secretion of the pituitary gland
hormones, resulting in hypopituitarism. Therefore, other
pituitary hormones and their target hormones should be
evaluated.
Magnetic resonance imaging (MRI) with contrast ad-
ministration is the best imaging technique to pinpoint the
pituitary source of excess GH. This technique makes it
possible to visualize and locate, in relation to surrounding
structures, adenomas larger than 2mm in diameter. At
the time of diagnosis, over 75% show a macroadenoma
(>10mm in diameter), which grows into the cavernous
sinus or suprasellar region. In rare cases, in patients with
acromegaly and unremarkable pituitary MR imaging and
no evidence of ectopic GH or GHRH production (CT or
MRI thoracic and abdominal negative), a transsphenoidal
pituitary exploration is a reasonable approach andmay result
in clinical improvement and biochemical cure in the hands of
experienced surgeon [68].
As previously discussed, acromegaly is rarely caused
by ectopic tumors that produce GHRH (only 0.5% of
acromegalic cases) or GH [8]. The suspicion for ectopic
sources should arise when there is a biochemical diagnosis
of acromegaly, with radiographic absence of a pituitary
tumor or presence of diﬀuse pituitary enlargement or when
the postsurgical pathology report indicates somatotroph
hyperplasia rather than adenoma. The measurement of
plasma GHRH concentrations can be very helpful. Total
body scintigraphy with radio-labeled somatostatin should
be performed in order to localize the tumor. A definitive
diagnosis of ectopic GHRH production can be made either
by showing an arteriovenous gradient of GHRH across the
tumor bed or by normalization of GHRH, IGF-I, and GH
levels after removal of the tumor [69]. Figure 1 illustrates the
algorithm for the diagnosis of acromegaly.
It has been suggested that the mortality rate in patients
with acromegaly is correlated with the degree of control
of GH. The mortality rate from cancer can be stratified
according to GH levels aftercare and may be similar to
that of the nonacromegalic population. The standardized
mortality rate for acromegaly is 1.72. Mortality is related to
GH levels of over 2–2.5 μg/L and less clearly with elevated
IGF-I [70]. Treatment with radiotherapy may be associated
with increased mortality [71]. A meta-analysis of mortality
ratios in patients with acromegaly found all-cause mortality
increased in comparison to the general population. Although
the mortality risk has decreased due to modern treatment
strategies, including transsphenoidal surgery, there is still a
32% increased all-causemortality risk in acromegaly. Further
investigation is required in order to determine whether
newer treatment strategies in acromegaly are accompanied
by a further improvement in survival [72].
Clinical and biochemical control is aimed at correcting
tumor compression, controlling biochemical markers to
normal levels, and reducing morbidity and mortality to the
expected rate for the normal population. According to the
2010 consensus criteria, biochemical control of acromegaly
is achieved when circulating IGF-I is reduced to an age-
and sex-adjusted normal range and GH during OGTT is
<0.4 μg/L or random GH is <1 μg/L [63]. The prognosis
of acromegaly has improved in recent years, and adequate
hormonal disease control is achieved in most cases, allowing
life expectancy similar to that of the general population [63].
4. Conclusion
Acromegaly is an uncommon disease, which in most cases
is due to a pituitary tumor. It has a wide variety of clinical
manifestations, including acral and soft tissue overgrowth,
joint pain, diabetes mellitus, hypertension, and heart and
respiratory failure. Acromegaly is usually diagnosed by
increased IGF-I and GH after an OGTT. Its treatment
reduces complications and mortality.
Conflict of Interests
None of the authors have any conflict of interest related to
this article.
Acknowledgments
This paper is supported in part by FIS del Instituto de
Salud Carlos III PI070413, PI10/00088, and Xunta de Galicia
PS07/12, INCITE08ENA916110ES, INCITE09E1R91634ES,
IN845B-2010/187, 10CSA916014PR, Spain.
8 International Journal of Endocrinology
References
[1] S. Melmed, “Acromegaly pathogenesis and treatment,” Journal
of Clinical Investigation, vol. 119, no. 11, pp. 3189–3202, 2009.
[2] I. M. Holdaway and C. Rajasoorya, “Epidemiology of acro-
megaly,” Pituitary, vol. 2, no. 1, pp. 29–41, 1999.
[3] S. L. Asa and S. Ezzat, “The pathogenesis of pituitary tumors,”
Annual Review of Pathology, vol. 4, pp. 97–126, 2009.
[4] M. T. Diz-Lois, J. Garcia-Buela, F. Suarez, S. Sangiao-
Alvarellos, O. Vidal, and F. Cordido, “Altered fasting and post-
prandial plasma ghrelin levels in patients with liver failure are
normalized after liver transplantation,” European Journal of
Endocrinology, vol. 163, no. 4, pp. 609–616, 2010.
[5] E. Outeirin˜o-Blanco, J. Garcia-Buela, S. Sangiao-Alvarellos, S.
Pertega-Diaz, T.Martinez-Ramonde, and F. Cordido, “Growth
hormone, ghrelin and peptide YY secretion after oral glucose
administration in healthy and obese women,” Hormone and
Metabolic Research, vol. 43, no. 8, pp. 580–586, 2011.
[6] S. Sangiao-Alvarellos, S. Helmling, M. J. Va´zquez, S.
Klussmann, and F. Cordido, “Ghrelin neutralization during
fasting-refeeding cycle impairs the recuperation of body
weight and alters hepatic energy metabolism,” Molecular and
Cellular Endocrinology, vol. 335, no. 2, pp. 177–188, 2011.
[7] F. Gołkowski, M. Buziak-Bereza, A. Stefan´ska et al., “A case
of GH and TSH secreting pituitary macroadenoma,” Przeglad
Lekarski, vol. 63, no. 2, pp. 106–108, 2006.
[8] M. L. Isidro, P. Iglesias Diaz, X. Matias-Guiu, and F. Cordido,
“Acromegaly due to a growth hormone-releasing hormone-
secreting intracranial gangliocytoma,” Journal of Endocrinolog-
ical Investigation, vol. 28, no. 2, pp. 162–165, 2005.
[9] I. M. Holdaway, R. C. Rajasoorya, and G. D. Gamble, “Factors
influencing mortality in acromegaly,” Journal of Clinical
Endocrinology and Metabolism, vol. 89, no. 2, pp. 667–674,
2004.
[10] M. R. Drange, N. R. Fram, V. Herman-Bonert, and S. Melmed,
“Pituitary tumor registry: a novel clinical resource,” Journal of
Clinical Endocrinology and Metabolism, vol. 85, no. 1, pp. 168–
174, 2000.
[11] P. Kamenicky, A. Blanchard, M. Frank et al., “Body fluid ex-
pansion in acromegaly is related to enhanced epithelial
sodium channel (ENaC) activity,” Journal of Clinical Endocri-
nology and Metabolism, vol. 96, no. 7, pp. 2127–2135, 2011.
[12] T. Abe, L. A. Tara, and D. K. Ludecke, “Growth hormone-
secreting pituitary adenomas in childhood and adolescence:
features and results of transnasal surgery,” Neurosurgery, vol.
45, no. 1, pp. 1–10, 1999.
[13] S. Melmed, “Acromegaly,” New England Journal of Medicine,
vol. 355, no. 24, pp. 2558–2573, 2006.
[14] A. Ben-Shlomo and S. Melmed, “Skin manifestations in
acromegaly,” Clinics in Dermatology, vol. 24, no. 4, pp. 256–
259, 2006.
[15] Z. Killinger, J. Payer, I. Lazu´rova´ et al., “Arthropathy in
acromegaly,” Rheumatic Disease Clinics of North America, vol.
36, no. 4, pp. 713–720, 2010.
[16] N. R. Biermasz,M. J. E.Wassenaar, A. A. VanDer Klaauw et al.,
“Pretreatment insulin-like growth factor-I concentrations pre-
dict radiographic osteoarthritis in acromegalic patients with
long-term cured disease,” Journal of Clinical Endocrinology and
Metabolism, vol. 94, no. 7, pp. 2374–2379, 2009.
[17] M. J. Wassenaar, N. R. Biermasz, N. A.T. Hamdy et al., “High
prevalence of vertebral fractures despite normal bone mineral
density in patients with long-term controlled acromegaly,”
European Journal of Endocrinology, vol. 164, no. 4, pp. 475–
483, 2011.
[18] M. Bolanowski, J. Daroszewski, M. Me¸dras´, and B. Zadrozna-
S´liwka, “Bone mineral density and turnover in patients with
acromegaly in relation to sex, disease activity, and gonadal
function,” Journal of Bone andMineral Metabolism, vol. 24, no.
1, pp. 72–78, 2006.
[19] T. Ueland, S. L. Fougner, K. Godang, T. Schreiner, and J.
Bollerslev, “Serum GH and IGF-I are significant determinants
of bone turnover but not bone mineral density in active
acromegaly: a prospective study of more than 70 consecutive
patients,” European Journal of Endocrinology, vol. 155, no. 5,
pp. 709–715, 2006.
[20] A. Scillitani, C. Battista, I. Chiodini et al., “Bone mineral
density in acromegaly: the eﬀect of gender, disease activity and
gonadal status,” Clinical Endocrinology, vol. 58, no. 6, pp. 725–
731, 2003.
[21] G. Mazziotti, A. Bianchi, S. Bonadonna et al., “Prevalence of
vertebral fractures inmen with acromegaly,” Journal of Clinical
Endocrinology and Metabolism, vol. 93, no. 12, pp. 4649–4655,
2008.
[22] R. Scarpa, D. De Brasi, R. Pivonello et al., “Acromegalic axial
arthropathy: a clinical case-control study,” Journal of Clinical
Endocrinology and Metabolism, vol. 89, no. 2, pp. 598–603,
2004.
[23] A. Colao, P. Marzullo, C. Di Somma, and G. Lombardi,
“Growth hormone and the heart,” Clinical Endocrinology, vol.
54, no. 2, pp. 137–154, 2001.
[24] G. Vitale, R. Pivonello, G. Lombardi, and A. Colao, “Cardiac
abnormalities in acromegaly: pathophysiology and implica-
tions for management,” Treatments in Endocrinology, vol. 3,
no. 5, pp. 309–318, 2004.
[25] M. Sue, A. Yoshihara, Y. Okubo et al., “A case of juvenile
acromegaly that was initially diagnosed as severe congestive
heart failure from acromegaly-induced dilated cardiomyopa-
thy,” Internal Medicine, vol. 49, no. 19, pp. 2117–2121, 2010.
[26] G. Kehaly, K. V. Olshausen, S. Mohr-Kahaly et al., “Arrhythmia
profile in acromegaly,” European Heart Journal, vol. 13, no. 1,
pp. 51–56, 1992.
[27] A. Colao, L. Spinelli, P. Marzullo et al., “High prevalence of
cardiac valve disease in acromegaly: an observational, analyt-
ical, case-control study,” Journal of Clinical Endocrinology and
Metabolism, vol. 88, no. 7, pp. 3196–3201, 2003.
[28] A. Colao, S. Spiezia, G. Cerbone et al., “Increased arterial
intima-media thickness by B-M mode echodoppler ultra-
sonography in acromegaly,” Clinical Endocrinology, vol. 54, no.
4, pp. 515–524, 2001.
[29] H. Akutsu, J. Kreutzer, G. Wasmeier et al., “Acromegaly per
se does not increase the risk for coronary artery disease,”
European Journal of Endocrinology, vol. 162, no. 5, pp. 879–
886, 2010.
[30] S. Cannavo, B. Almoto, G. Cavalli et al., “Acromegaly and
coronary disease: an integrated evaluation of conventional
coronary risk factors and coronary calcifications detected by
computed tomography,” Journal of Clinical Endocrinology and
Metabolism, vol. 91, no. 10, pp. 3766–3772, 2006.
[31] F. Bogazzi, L. Battolla, C. Spinelli et al., “Risk factors for
development of coronary heart disease in patients with
acromegaly: a five-year prospective study,” Journal of Clinical
Endocrinology and Metabolism, vol. 92, no. 11, pp. 4271–4277,
2007.
[32] C. Berg, S. Petersenn, H. Lahner et al., “Cardiovascular risk
factors in patients with uncontrolled and long-term acro-
megaly: comparison with matched data from the general
population and the eﬀect of disease control,” Journal of Clinical
International Journal of Endocrinology 9
Endocrinology and Metabolism, vol. 95, no. 8, pp. 3648–3656,
2010.
[33] L. Sacca, A. Cittadini, and S. Fazio, “Growth hormone and the
heart,” Endocrine Reviews, vol. 15, no. 5, pp. 555–573, 1994.
[34] N. Moller, J. O. L. Jorgensen, N. Abildgard, L. Orskov, O.
Schmitz, and J. S. Christiansen, “Eﬀects of growth hormone on
glucose metabolism,” Hormone Research, vol. 36, supplement
1, pp. 32–35, 1991.
[35] A. Kreze, E. Kreze-Spirova, and M. Mikulecky, “Risk factors
for glucose intolerance in active acromegaly,” Brazilian Journal
of Medical and Biological Research, vol. 34, no. 11, pp. 1429–
1433, 2001.
[36] H. Biering, G. Knappe, H. Gerl, and H. Lochs, “Prevalence of
diabetes in acromegaly and Cushing syndrome,” Acta Medica
Austriaca, vol. 27, no. 1, pp. 27–31, 2000.
[37] S. Kasayama, M. Otsuki, M. Takagi et al., “Impaired β-cell
function in the presence of reduced insulin sensitivity de-
termines glucose tolerance status in acromegalic patients,”
Clinical Endocrinology, vol. 52, no. 5, pp. 549–555, 2000.
[38] A. Colao, R. Baldelli, P. Marzullo et al., “Systemic hypertension
and impaired glucose tolerance are independently correlated
to the severity of the acromegalic cardiomyopathy,” Journal of
Clinical Endocrinology and Metabolism, vol. 85, no. 1, pp. 193–
199, 2000.
[39] G. Sesmilo, W. P. Fairfield, L. Katznelson et al., “Cardiovascu-
lar risk factors in acromegaly before and after normalization
of serum IGF-I levels with the GH antagonist pegvisomant,”
Journal of Clinical Endocrinology and Metabolism, vol. 87, no.
4, pp. 1692–1699, 2002.
[40] R. Manara, P. Maﬀei, V. Citton et al., “Increased rate of
intracranial saccular aneurysms in acromegaly: anMR angiog-
raphy study and review of the literature,” Journal of Clinical
Endocrinology and Metabolism, vol. 96, no. 5, pp. 1292–1300,
2011.
[41] B. D. W. Harrison, K. A. Millhouse, M. Harrington, and J. D.
N. Nabarro, “Lung function in acromegaly,” Quarterly Journal
of Medicine, vol. 47, no. 188, pp. 517–532, 1978.
[42] R. R. Grunstein, K. Y. Ho, M. Berthon-Jones, D. Stewart,
and C. E. Sullivan, “Central sleep apnea is associated with
increased ventilatory response to carbon dioxide and hyper-
secretion of growth hormone in patients with acromegaly,”
American Journal of Respiratory and Critical Care Medicine,
vol. 150, no. 2, pp. 496–502, 1994.
[43] P. Attal and P. Chanson, “Endocrine aspects of obstructive
sleep apnea,” Journal of Clinical Endocrinology andMetabolism,
vol. 95, no. 2, pp. 483–495, 2010.
[44] E. De Menis, A. Giustina, A. Colao et al., “Assessment of
the awareness and management of sleep apnea syndrome in
acromegaly,” Journal of Endocrinological Investigation, vol. 34,
no. 1, pp. 60–64, 2011.
[45] L. M. Fatti, M. Scacchi, A. I. Pincelli, E. Lavezzi, and F.
Cavagnini, “Prevalence and pathogenesis of sleep apnea and
lung disease in acromegaly,” Pituitary, vol. 4, no. 4, pp. 259–
262, 2001.
[46] R. Shah, A. Licata, N. M. Oyesiku, and A. G. Ioachimescu,
“Acromegaly as a cause of 1,25-dihydroxyvitamin D-
dependent hypercalcemia: case reports and review of the
literature,” Pituitary. In press.
[47] S. Cannavo`, R. Condurso, M. Ragonese et al., “Increased
prevalence of restless legs syndrome in patients with
acromegaly and eﬀects on quality of life assessed by Acro-
QoL,” Pituitary, vol. 14, no. 4, pp. 328–334, 2011.
[48] M. J. E. Wassenaar, M. Cazemier, N. R. Biermasz et al.,
“Acromegaly is associated with an increased prevalence of
colonic diverticula: a case-control study,” Journal of Clinical
Endocrinology and Metabolism, vol. 95, no. 5, pp. 2073–2079,
2010.
[49] S. M. Orme, R. J. Q. Mcnally, R. A. Cartwright, and P. E.
Belchetz, “Mortality and cancer incidence in acromegaly: a
retrospective cohort study,” Journal of Clinical Endocrinology
and Metabolism, vol. 83, no. 8, pp. 2730–2734, 1998.
[50] A. G. Renehan and B. M. Brennan, “Acromegaly, growth
hormone and cancer risk,” Best Practice and Research, vol. 22,
no. 4, pp. 639–657, 2008.
[51] A. Colao, R. Pivonello, R. S. Auriemma et al., “The association
of fasting insulin concentrations and colonic neoplasms in
acromegaly: a colonoscopy-based study in 210 patients,”
Journal of Clinical Endocrinology and Metabolism, vol. 92, no.
10, pp. 3854–3860, 2007.
[52] B. Levin, D. A. Lieberman, B. McFarland et al., “Screening and
surveillance for the early detection of colorectal cancer and
adenomatous polyps,” Gastroenterology, vol. 134, no. 5, pp.
1570–1595, 2008.
[53] P. Dutta, A. Bhansali, K. Vaiphei et al., “Colonic neoplasia in
acromegaly: increased proliferation or deceased apoptosis?”
Pituitary. In press.
[54] S. M. Webb, F. Casaneuva, and J. A. H. Wass, “Oncological
complications of excess GH in acromegaly,” Pituitary, vol. 5,
no. 1, pp. 21–25, 2002.
[55] F. R. P. Barbosa, L. Vieira Neto, G. A. B. Lima, L. E.
Wildemberg, R. Portugal, and M. R. Gadelha, “Hematologic
neoplasias and acromegaly,” Pituitary, vol. 14, no. 4, pp. 377–
381, 2009.
[56] A. K. Annamalai, E. L. Gayton, A. Webb et al., “Increased
prevalence of gallbladder polyps in acromegaly,” Journal of
Clinical Endocrinology and Metabolism, vol. 96, no. 7, pp.
E1120–E1125, 2011.
[57] P. W. Rosario and M. R. Calsolari, “Screening for acromegaly
by application of a simple questionnaire evaluating the
enlargement of extremities in adult patients seen at primary
health care units,” Pituitary. In press.
[58] H. J. Schneider, R. P. Kosilek, M. Gu¨nther et al., “A novel
approach to the detection of acromegaly: accuracy of diag-
nosis by automatic face classification,” Journal of Clinical
Endocrinology and Metabolism, vol. 96, no. 7, pp. 2074–2080,
2011.
[59] E. V. Dimaraki, C. A. Jaﬀe, R. Demott-Friberg, W. F. Chandler,
and A. L. Barkan, “Acromegaly with apparently normal GH
secretion: implications for diagnosis and follow-up,” Journal
of Clinical Endocrinology and Metabolism, vol. 87, no. 8, pp.
3537–3542, 2002.
[60] A. Giustina, A. Barkan, F. F. Casanueva et al., “Criteria for
cure of acromegaly: a consensus statement,” Journal of Clinical
Endocrinology and Metabolism, vol. 85, no. 2, pp. 526–529,
2000.
[61] R. A. Cordero and A. L. Barkan, “Current diagnosis of
acromegaly,” Reviews in Endocrine and Metabolic Disorders,
vol. 9, no. 1, pp. 13–19, 2008.
[62] A. M. Arafat, M. Mo¨hlig, M. O. Weickert et al., “Growth
hormone response during oral glucose tolerance test: the
impact of assay method on the estimation of reference values
in patients with acromegaly and in healthy controls, and the
role of gender, age, and body mass index,” Journal of Clinical
Endocrinology and Metabolism, vol. 93, no. 4, pp. 1254–1262,
2008.
[63] A. Giustina, P. Chanson, M. D. Bronstein et al., “A consen-
sus on criteria for cure of acromegaly,” Journal of Clinical
10 International Journal of Endocrinology
Endocrinology and Metabolism, vol. 95, no. 7, pp. 3141–3148,
2010.
[64] A. Pokrajac, G. Wark, A. R. Ellis, J. Wear, G. E. Wieringa,
and P. J. Trainer, “Variation in GH and IGF-I assays limits
the applicability of international consensus criteria to local
practice,” Clinical Endocrinology, vol. 67, no. 1, pp. 65–70,
2007.
[65] A. Ribeiro-Oliveira Jr., A. T. Faje, and A. L. Barkan, “Limited
utility of oral glucose tolerance test in biochemically active
acromegaly,” European Journal of Endocrinology, vol. 164, no.
1, pp. 17–22, 2011.
[66] M. Bidlingmaier and P. U. Freda, “Measurement of human
growth hormone by immunoassays: current status, unsolved
problems and clinical consequences,” Growth Hormone and
IGF Research, vol. 20, no. 1, pp. 19–25, 2010.
[67] J. J. Puder, S. Nilavar, K. D. Post, and P. U. Freda, “Relationship
between disease-related morbidity and biochemical markers
of activity in patients with acromegaly,” Journal of Clinical
Endocrinology and Metabolism, vol. 90, no. 4, pp. 1972–1978,
2005.
[68] S. Daud, A. H. Hamrahian, R. J. Weil, M. Hamaty, R. A.
Prayson, and L. Olansky, “Acromegaly with negative pituitary
MRI and no evidence of ectopic source: the role of transphe-
noidal pituitary exploration?” Pituitary, vol. 14, no. 4, pp. 414–
417, 2011.
[69] M. Losa and K. Von Werder, “Pathophysiology and clinical
aspects of the ectopic GH-releasing hormone syndrome,”
Clinical Endocrinology, vol. 47, no. 2, pp. 123–135, 1997.
[70] I. M. Holdaway, M. J. Bolland, and G. D. Gamble, “A meta-
analysis of the eﬀect of lowering serum levels of GH and IGF-I
on mortality in acromegaly,” European Journal of Endocrinolo-
gy, vol. 159, no. 2, pp. 89–95, 2008.
[71] M. Sherlock, R. C. Reulen, A. A. Alonso et al., “ACTH
deficiency, higher doses of hydrocortisone replacement, and
radiotherapy are independent predictors of mortality in
patients with acromegaly,” Journal of Clinical Endocrinology
and Metabolism, vol. 94, no. 11, pp. 4216–4223, 2009.
[72] O.M.Dekkers, N. R. Biermasz, A.M. Pereira, J. A. Romijn, and
J. P. Vandenbroucke, “Mortality in acromegaly: a metaanaly-
sis,” Journal of Clinical Endocrinology and Metabolism, vol. 93,
no. 1, pp. 61–67, 2008.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
